Cargando…
High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer
BACKGROUND: Taxol resistance in serous ovarian cancer is responsible for its poor prognosis, yet the underlying mechanism is still poorly understood. Thus, we probed the mechanism of Taxol resistance in serous ovarian cancer with multiple bioinformatic methods to provide novel insights into potentia...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044796/ https://www.ncbi.nlm.nih.gov/pubmed/35477477 http://dx.doi.org/10.1186/s13048-022-00986-2 |
_version_ | 1784695181820297216 |
---|---|
author | Shen, Yuqing Lin, Hui Chen, Kelie Ge, Wanzhong Xia, Dajing Wu, Yihua Lu, Weiguo |
author_facet | Shen, Yuqing Lin, Hui Chen, Kelie Ge, Wanzhong Xia, Dajing Wu, Yihua Lu, Weiguo |
author_sort | Shen, Yuqing |
collection | PubMed |
description | BACKGROUND: Taxol resistance in serous ovarian cancer is responsible for its poor prognosis, yet the underlying mechanism is still poorly understood. Thus, we probed the mechanism of Taxol resistance in serous ovarian cancer with multiple bioinformatic methods to provide novel insights into potential therapies. METHODS: The differentially expressed genes (DEGs) in Taxol-sensitive and Taxol-resistant cell lines and their relationship with the overall survival (OS) and progression-free interval (PFI) of ovarian cancer patients were analyzed using gene expression datasets from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The role of receptor interacting serine/threonine kinase 2 (RIPK2) was validated via identification of its coexpressed genes, functional analysis and generation of a protein-protein interaction (PPI) network. The single sample gene set enrichment analysis (ssGSEA) was used to explore immune infiltration, and genomic alterations of RIPK2 were also analyzed via cBio Cancer Genomics Portal (cBioProtal). RESULTS: RIPK2 was highly expressed in Taxol resistant ovarian cancer cell lines, and its high expression was also linked with shorter OS and PFI in serous ovarian cancer patients. The PPI network analysis and pathway analysis demonstrated that RIPK2 might participate in the positive regulation of NF-κB transcription factor activity. RIPK2 expression was related to tumor microenvironment alterations, which might participate in the formation of Taxol resistance. CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-κB inflammatory pathway activation and tumor microenvironment changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-00986-2. |
format | Online Article Text |
id | pubmed-9044796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90447962022-04-28 High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer Shen, Yuqing Lin, Hui Chen, Kelie Ge, Wanzhong Xia, Dajing Wu, Yihua Lu, Weiguo J Ovarian Res Research BACKGROUND: Taxol resistance in serous ovarian cancer is responsible for its poor prognosis, yet the underlying mechanism is still poorly understood. Thus, we probed the mechanism of Taxol resistance in serous ovarian cancer with multiple bioinformatic methods to provide novel insights into potential therapies. METHODS: The differentially expressed genes (DEGs) in Taxol-sensitive and Taxol-resistant cell lines and their relationship with the overall survival (OS) and progression-free interval (PFI) of ovarian cancer patients were analyzed using gene expression datasets from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The role of receptor interacting serine/threonine kinase 2 (RIPK2) was validated via identification of its coexpressed genes, functional analysis and generation of a protein-protein interaction (PPI) network. The single sample gene set enrichment analysis (ssGSEA) was used to explore immune infiltration, and genomic alterations of RIPK2 were also analyzed via cBio Cancer Genomics Portal (cBioProtal). RESULTS: RIPK2 was highly expressed in Taxol resistant ovarian cancer cell lines, and its high expression was also linked with shorter OS and PFI in serous ovarian cancer patients. The PPI network analysis and pathway analysis demonstrated that RIPK2 might participate in the positive regulation of NF-κB transcription factor activity. RIPK2 expression was related to tumor microenvironment alterations, which might participate in the formation of Taxol resistance. CONCLUSIONS: Our studies suggested that high expression of RIPK2 is related to Taxol resistance in serous ovarian cancer, and that RIPK2 induces Taxol resistance through NOD1/RIPK2/NF-κB inflammatory pathway activation and tumor microenvironment changes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-00986-2. BioMed Central 2022-04-27 /pmc/articles/PMC9044796/ /pubmed/35477477 http://dx.doi.org/10.1186/s13048-022-00986-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Shen, Yuqing Lin, Hui Chen, Kelie Ge, Wanzhong Xia, Dajing Wu, Yihua Lu, Weiguo High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title | High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title_full | High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title_fullStr | High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title_full_unstemmed | High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title_short | High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer |
title_sort | high expression of ripk2 is associated with taxol resistance in serous ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044796/ https://www.ncbi.nlm.nih.gov/pubmed/35477477 http://dx.doi.org/10.1186/s13048-022-00986-2 |
work_keys_str_mv | AT shenyuqing highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT linhui highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT chenkelie highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT gewanzhong highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT xiadajing highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT wuyihua highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer AT luweiguo highexpressionofripk2isassociatedwithtaxolresistanceinserousovariancancer |